SK Hynix shares surge to 26-yr high on Amazon data center collaboration
Investing.com - Canaccord Genuity raised its price target on Boston Scientific (NYSE:BSX) to $132.00 from $131.00 while maintaining a Buy rating following the company’s 2025 Investor Day. The medical device maker, currently valued at $144.66 billion with a strong "GREAT" financial health score according to InvestingPro, has seen its stock trade at $97.63.
The medical device maker outlined its growth strategy for 2026-2028, projecting organic sales compound annual growth rate (CAGR) of over 10% and annual adjusted operating margin expansion of approximately 50 basis points during this period. The company’s current revenue growth of 21.44% and impressive gross profit margin of 68.04% support these ambitious targets.
Boston Scientific expects its operating margin to approach 30% by 2028, which Canaccord notes is slightly ahead of consensus estimates, though the overall long-range plan aligns with broader market expectations. While InvestingPro analysis suggests the stock is currently trading above its Fair Value, 12 additional exclusive ProTips are available to help investors make informed decisions.
The company plans to leverage growth from successful product lines like WATCHMAN and FARAPULSE while expanding into new fields including IVL, TCAR, renal denervation, OAB, and circulatory support to drive organic growth.
Canaccord highlighted Boston Scientific’s continued investment in research and development and venture capital investments as factors that position the company as "the continued leader in strategic Med-Tech."
In other recent news, Boston Scientific has been the focus of several analyst updates and industry developments. BTIG raised its price target for the company to $132, maintaining a Buy rating, following Boston Scientific’s investor day where the company outlined ambitious financial targets for 2026-2028, including a 10%+ organic revenue growth rate and double-digit adjusted earnings per share growth. RBC Capital reiterated its Outperform rating with a $125 price target, showing continued confidence in the company’s future. Similarly, Piper Sandler reiterated its Overweight rating with a $115 price target, expressing optimism about the CHAMPION-AF study, which could enhance the Watchman franchise. TD Cowen also reiterated its Buy rating and $115 price target, anticipating that Boston Scientific will announce a long-range plan targeting 10-12% sales growth through 2028. Meanwhile, the Trump administration launched a Section 232 investigation into medical devices, which could introduce tariff concerns for the industry. This investigation covers a wide range of medical products, including personal protective equipment and medical devices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.